RecruitingPHASE1, PHASE2NCT06709495

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Studying Bone sarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
David S Shulman, MD
Principal Investigator
David Shulman, MD
Dana-Farber Cancer Institute
Intervention
PEEL-224(drug)
Enrollment
63 enrolled
Eligibility
12-49 years · All sexes
Timeline
2025 – 2029

Study locations (3)

Collaborators

Peel Therapeutics Inc

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06709495 on ClinicalTrials.gov

Other trials for Bone sarcoma

Additional recruiting or active studies for the same condition.

See all trials for Bone sarcoma →

← Back to all trials